Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3693-8448
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.09 million
Profitability
Miscellaneous
Employees17
OptionableOptionable
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.27 million. Galmed Pharmaceuticals had a negative return on equity of 18.55% and a negative net margin of 423.62%. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
7 brokerages have issued twelve-month price targets for Galmed Pharmaceuticals' shares. Their forecasts range from $20.00 to $59.00. On average, they anticipate Galmed Pharmaceuticals' share price to reach $35.75 in the next twelve months. This suggests a possible upside of 365.5% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.
What is the consensus analysts' recommendation for Galmed Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.
Has Galmed Pharmaceuticals been receiving favorable news coverage?
News articles about GLMD stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Forty Seven (FTSV), Corium International (CORI), Theratechnologies (THERF), Collegium Pharmaceutical (COLL), Obseva (OBSV), ZEALAND PHARMA/S (ZEAL), Clementia Pharmaceuticals (CMTA), Odonate Therapeutics (ODT), Cytokinetics (CYTK), Aptorum Group (APM), Innate Pharma (IPHYF), Progenics Pharmaceuticals (PGNX), Five Prime Therapeutics (FPRX), Osmotica Pharmaceuticals (OSMT) and Beyondspring (BYSI).
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Yohai Stenzler, CFO & Controller (Age 36)
- Mr. Guy Nehemya, VP of Operations (Age 34)
- Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
- Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 36)
- Dr. Tali Gorfine, Chief Medical Officer (Age 49)
Who are Galmed Pharmaceuticals' major shareholders?
Galmed Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (5.25%), Ibex Investors LLC (3.14%), First Midwest Bank Trust Division (1.35%), UBS Oconnor LLC (0.67%), Raymond James & Associates (0.54%) and Premier Asset Management LLC (0.46%).
Which institutional investors are selling Galmed Pharmaceuticals stock?
GLMD stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Menta Capital LLC, UBS Oconnor LLC and Nantahala Capital Management LLC.
Which institutional investors are buying Galmed Pharmaceuticals stock?
GLMD stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Ibex Investors LLC, Premier Asset Management LLC, Raymond James & Associates, ETF Managers Group LLC, BlackRock Inc. and Northern Trust Corp.
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $7.68.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $122.19 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.
What is Galmed Pharmaceuticals' official website?
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
